Skip to content

Clinical trials

Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in Russia

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma Country / region: Russia Clear all

45 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20061
20082
20091
20102
20121
20132
20142
20154
20162
20171
20182
20194
20204
20217
20221
20232
20244
20252

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed16
Unknown status11
Recruiting7
Active, not recruiting5
Terminated4
Not yet recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Federal Research Institute of Pediatric Hematology, Oncology and Immunology14
National Research Center for Hematology, Russia5
St. Petersburg State Pavlov Medical University5
Amgen4
Bristol-Myers Squibb3
Novartis Pharmaceuticals3
Institut de Recherches Internationales Servier2
AO GENERIUM1
AbbVie1
Affimed GmbH1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma45
Leukemia, Myeloid, Acute12
Myelodysplastic Syndromes10
Leukemia, Biphenotypic, Acute7
Lymphoma, Non-Hodgkin6
Neoplasms6
Leukemia4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive4
Lymphoma4
Immune System Diseases3

Trials

Showing 1 to 25 of 45. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.